Get Premium to unlock powerful stock data
Iovance Biotherapeutics Inc logo

Iovance Biotherapeutics Inc

$ 14.78 +0.42 (+2.92%) 04:00 PM EST
P/E:
At Loss
P/B:
4.22
Market Cap:
$ 2.32B
Enterprise V:
$ 1.85B
Volume:
1.71M
Avg Vol (2M):
2.07M
Also Trade In:
Volume:
1.71M
Market Cap $:
2.32B
PE Ratio:
At Loss
Avg Vol (2-Month):
2.07M
Enterprise Value $:
1.85B
PB Ratio:
4.22
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Iovance Biotherapeutics Inc
NAICS : 325411 SIC : 2834
825 Industrial Road, Suite 400, San Carlos, CA, USA, 94070
Description
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. Its lead pipeline candidate, LN-145, is an adoptive cell therapy using tumor-infiltrating lymphocytes to treat patients with refractory metastatic melanoma.
Name Current Vs Industry Vs History
Cash-To-Debt 6.04
Equity-to-Asset 0.79
Debt-to-Equity 0.15
Debt-to-EBITDA -0.24
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 44.31
9-Day RSI 46.12
14-Day RSI 46.11
6-1 Month Momentum % -13.04
12-1 Month Momentum % -8.44

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 6.36
Quick Ratio 6.36
Cash Ratio 6.26

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -8.4

Financials (Next Earnings Date:2022-08-05 Est.)

IOVA's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:IOVA

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Performance
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -2.29
Beta 0.21
Volatility % 67.86
14-Day RSI 46.11
14-Day ATR ($) 1.118308
20-Day SMA ($) 14.6605
12-1 Month Momentum % -8.44
52-Week Range ($) 11.91 - 28
Shares Outstanding (Mil) 157.17

Piotroski F-Score Details

Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Iovance Biotherapeutics Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More